247 Wallst
12 Apr 2026, 12:49 UTC · 25w ago
Verdict
Headline takes no side. We score NTLA +0.70 — strongly bullish.
+0.70strongly bullish
More positive than 82% of ticker scores this week
Which stocks this story touches
More positive than 82% of ticker scores this week
Highlighted for its year-to-date surge and potential as a platform play for gene drive applications.
More positive than 76% of ticker scores this week
Identified as a platform provider that could benefit from the expansion of genome editing into invasive species control.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of ticker scores this week
Positioned as a foundational infrastructure play for the potentially massive gene drive market with positive analyst targets.
More positive than 62% of ticker scores this week
Mentioned positively in the context of an expanded collaboration with Intellia Therapeutics.
Near neutral — 92% of ticker scores this week are stronger
The article mentions the company is reporting earnings but provides no sentiment or outlook.
More positive than 56% of relationship scores this week
[mutual] Intellia Therapeutics announced an expansion to its collaboration with Regeneron Pharmaceuticals.
More positive than 14% of relationship scores this week
[mutual] Both companies are positioned as platform plays providing genome editing infrastructure for gene drive applications.
More positive than 14% of relationship scores this week
[mutual] Both companies are positioned as platform plays providing genome editing infrastructure for gene drive applications.
More positive than 14% of relationship scores this week
[mutual] Both companies are positioned as platform plays providing genome editing infrastructure for gene drive applications.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
TechCrunch
3h ago
−3.1%
Price is moving against the score
$13.07 vs $13.49 close before publication (Apr 10) · not market-adjusted
NTLA chart →
